VVOS - Vivos Therapeutics again delays Q2 2022 results

• For the second time, Vivos Therapeutics has delayed the release of its Q2 2022 financial results .
• The release was first expected on August 15. However, on that date, the company said results would be delayed due to "ongoing Company analysis and related discussions between the Company and its independent registered public accountants regarding certain technical matters pertaining to the Company’s revenue recognition policies."
• Vivos ( NASDAQ: VVOS ) noted the results would come on August 22.
• On Monday, Vivos ( VVOS ) said the results would be further delayed based on discussions with its accountants "about a potential need to reevaluate how and when we recognize enrollment fees charged to new Vivos Integrated Providers."
• The medtech company added that further analysis is necessary, a process that "could take several weeks."
• Seeking Alpha's Quant Rating views Vivos ( VVOS ) as a strong sell.

For further details see: